Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on French Guiana Wellness Network.
Press releases published on August 12, 2025
Diabetic Ketoacidosis Market Driven by Rising Diabetes Prevalence and Innovative Emergency Care | DataM Intelligence
Diabetic Ketoacidosis market with insights on size, trends, key drivers, challenges, competitive landscape, and forecasts. TEXAS, TX, UNITED STATES, August 13, 2025 /EINPresswire.com/ -- The Global Diabetic Ketoacidosis Market reached US$ 1.5 billion in …
Contraceptive Device Market Expected to Hit USD 42.5 Billion by 2035 with a Remarkable 3.05% CAGR
Global Contraceptive Device Market Gears Up for Steady Growth as Demand for Diverse Family-Planning Solutions Rises U.S, NY, UNITED STATES, August 12, 2025 /EINPresswire.com/ -- The Contraceptive Device Market continues to gain strategic prominence …
Non-Surgical Aesthetic Device Market is Projected to Reach USD 6.5 Billion, with a Robust 5.4% CAGR Till 2035
Non-Surgical Aesthetic Device Market: Innovation Fuels Growth in Demand for Safe, Fast Beauty Solutions U.S, NY, UNITED STATES, August 12, 2025 /EINPresswire.com/ -- The Non-Surgical Aesthetic Device Market is expanding rapidly, reflecting a clear …
Neurovascular Thrombectomy Device Market is Poised to Growth USD 4.5 Billion by 2035 with Thriving CAGR of 5.54%
Neurovascular Thrombectomy Device Market Gears Up for Accelerated Expansion Amid Industry Innovation and Demand Surge. US, NY, UNITED STATES, August 12, 2025 /EINPresswire.com/ -- The Neurovascular Thrombectomy Device Market continues to capture …
Nitinol Medical Device Market Anticipated to Reach USD 6.5 Billion, at a Notable 5.4% CAGR by 2035
Nitinol Medical Device Market Gains Momentum as Shape-Memory Innovation Transforms Medical Technology US, NY, UNITED STATES, August 12, 2025 /EINPresswire.com/ -- The Nitinol Medical Device Market is entering a period of sustained growth, fueled by …
Maximus Ranks No. 27 on the 2025 Inc. 5000 List of America’s Fastest-Growing Private Companies
Los Angeles, CA, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, today announced Maximus is No. 27 on the annual Inc. 5000 list, the most prestigious ranking of the …
Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in H2 2026 Announced positive data from Phase 1b/2a RESOLVE supporting the potential of EP-104GI to improve the standard of …
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 • Cadisegliatin intellectual property portfolio expanded • Leadership team …
First Lady Anna Stein, NCDHHS and Morse Clinics Celebrate First Mobile Opioid Treatment Program Unit in North Carolina
Raleigh, NC, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Credentialed media are invited to attend the unveiling of the first Mobile Opioid Treatment Program (OTP) unit in North Carolina. Mobile OTPs reduce barriers to participation in treatment by making it easier …
Sienna Reports Second Quarter 2025 Financial Results and Publishes 2025 Impact Report
MARKHAM, Ontario, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced its financial results for the three and six months ended June 30, 2025. Highlights Average Same Property Occupancy in …
PetMed Express, Inc. Announces Management Changes
DELRAY BEACH, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (the “Company”) dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced that its Chief Executive Officer, Sandra Campos, and Chief Financial Officer, Robyn D’Elia …
Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates
- Duchenne (SGT-003): 15 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial and dosing remains ongoing; On track to discuss regulatory pathways with U.S. FDA in Q4 2025 - - FA (SGT-212): Phase 1b trial initiation expected in Q4 2025 - - CPVT (SGT- …
Zevra Reports Second Quarter 2025 Financial Results and Corporate Update
Q2 2025 net revenue of $25.9 million, driven by product net revenue of $21.8 million Completed sale of PRV for $150.0 million, bolstering the balance sheet as the Company executes on its commercial launches and development programs Submitted a Marketing …
LogicMark, Inc. Reports Second Quarter 2025 Results Highlighted by 22% Sales Growth
LOUISVILLE, Ky., Aug. 12, 2025 (GLOBE NEWSWIRE) -- LogicMark, Inc. (OTC: LGMK) (the Company), a provider of personal safety, personal emergency response systems (PERS), health communications devices, and technology for the growing care and safety economy, …
Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Received FDA feedback on Pre-IND Briefing Document reinforcing Company’s intention to advance investigational new drug (IND) submission for CUE-401 to address unmet need in the treatment of autoimmune disease. Announced strategic research collaboration and …
AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update
– Multiple near-term potential milestones, including anticipated completion of primary structure analysis and select functional analyses in 3Q’25 – – Type 2a meeting with the FDA anticipated in 4Q’25– – Cash runway expected to support operations through …
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
– Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference in Q4 2025 – Phase 2 ASPEN-Breast evorpacept trial design …
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphoma Initiated the PiNACLE pivotal trial of LYL314 in patients with large B-cell …
Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
Muzastotug (ADG126) Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial design elements. Company expects to begin enrolling …